Page 24 - rcv31n3.vp

Utilidad del score SAMe-TT 2R 2 en el control de la anticoagulación Revista Uruguaya de Cardiología
Andreina Gómez, Stephania Peixoto, María Azcúnaga y colaboradores Volumen 31 | nº 3 | Diciembre 2016

vitamin K antagonists. J Thromb Haemost 2004; ted 2015 Oct. 19]. Disponible en: http:// http://www.
2(2): 362-3. fda.gov/NewsEvents/Newsroom/PressAnnounce-
ments/ucm467300.htm.
24. Rosendaal FR, Cannegieter SC, van der Meer
FJ, Briët E. A method to determine the optimal in- 34. European Medicines Agency. Praxbind: idaruci-
tensity of oral anticoagulant therapy. Thromb Hae- zumab. London: EMA; c1995-2015. [updated 2015
most. 1993;69(3):236-9. Dec. 1]. Disponible en: http://www.ema.euro-
pa.eu/ema/index.jsp?curl=pages/medici-
25. Connolly SJ, Pogue J, Eikelboom J, Flaker
nes/human/medicines/003986/hu-
G,Commerford P, Franzosi MG, et al. Benefit of
man_med_001938.jsp&mid=WC0b01ac058001d124.
oral anticoagulant over antiplatelet therapy in atrial
fibrillation depends on the quality of international 35. Huisman M V, Lip GYH, Diener H-C, Brueck-
normalized ratio control achieved by centers and mann M, van Ryn J, Clemens A. Dabigatran ete-
countries as measured by time in therapeutic range. xilate for stroke prevention in patients with atrial fi-
Circulation. 2008;118(20):2029-37. brillation: resolving uncertainties in routine practi-
ce. Thromb Haemost. 2012;107(5):838-47.
26. De Caterina R, Husted S, Wallentin L, Andreot-
ti F, Arnesen H, Bachmann F, et al. Vitamin K 36. Tripodi A. Measuring the anticoagulant effect of di-
antagonists in heart disease: current status and pers- rect factor Xa inhibitors. Is the anti-Xa assay prefera-
pectives (Section III). Position paper of the ESC Wor- ble to the prothrombin time test? Thromb Haemost
king Group on Thrombosis—Task Force on Anticoa- 2011;105(4):735-6.
gulants in Heart Disease. Thromb Haemost.
37. Barrett YC, Wang Z, Frost C, Shenker A. Clini-
2013;110(6):1087-107.
cal laboratory measurement of direct factor Xa inhi-
27. De Caterina R, Husted S, Wallentin L, Andreot- bitors: anti-Xa assay is preferable to prothrombin
ti F, Arnesen H, Bachmann F, et al. General me- time assay. Thromb Haemost 2010;104(6):1263-71.
chanisms of coagulation and targets of anticoagu-
38. Pengo V, Crippa L, Falanga A, Finazzi G, Ma-
lants (Section I). Position paper of the ESC Working
rongiu F, Palareti G, et al. Questions and answers
Group on Thrombosis—Task Force on Anticoagu-
on the use of dabigatran and perspectives on the use
lants in Heart Disease. Thromb Haemost 2013;
of other new oral anticoagulants in patients with
109(4):569-79.
atrial fibrillation. A consensus document of the Ita-
28. National Institute for Health and Care Exce- lian Federation of Thrombosis Centers (FCSA).
llence. Atrial fibrillation: the management of atrial Thromb Haemost 2011;106(5):868-76.
fibrillation (clinical guideline 180). 2014. Disponible
39. Apostolakis S, Sullivan RM, Olshansky B, Lip
en: https://www.nice.org.uk/guidance/cg180.
GYH. Factors affecting quality of anticoagulation
29. Gallagher AM, Setakis E, Plumb JM, Clemens control among patients with atrial fibrillation on
A, van Staa T-P. Risks of stroke and mortality asso- warfarin: the SAMe-TTR score. Chest. 2013;144(5):
ciated with suboptimal anticoagulation in atrial fi- 1555-63.
brillation patients. Thromb Haemost. 2011;
40. Poli D, Antonucci E, Testa S, Lip GYH. A pros-
106(5):968-77.
pective validation of the SAME-TT2R 2 score: how to
30. Morgan CL, McEwan P, Tukiendorf A, Robin- identify atrial fibrillation patients who will have good
son PA, Clemens A, Plumb JM. Warfarin treat- anticoagulation control on warfarin. Intern Emerg
ment in patients with atrial fibrillation: observing Med. 2014;9(4):443-7.
outcomes associated with varying levels of INR con-
41. Gallego P, Roldán V, Marin F, Gálvez J, Valdés
trol. Thromb Res 2009;124(1):37-41.
M, Vicente V, et al. SAME-TT 2R 2 score, time in the-
31. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, rapeutic range and outcomes in anticoagulated pa-
Crijns HJGM, Lip GYH. A novel user-friendly sco- tients with atrial fibrillation. Am J Med 2014;
re (HAS-BLED) to assess 1-year risk of major blee- 127(11):1083-8.
ding in patients with atrial fibrillation: the Euro
42. Abumuaileq RR-Y, Abu-Assi E, Raposei-
Heart Survey. Chest 2010;138(5):1093-100.
ras-Roubin S, López-López A, Redondo-Dié-
32. Lip GYH, Frison L, Halperin JL, Lane DA. Com- guez A, Álvarez-Iglesias D, et al. Evaluation of
parative validation of a novel risk score for predicting SAMe- TT 2R 2 risk score for predicting the quality of
bleeding risk in anticoagulated patients with atrial anticoagulation control in a real-world cohort of pa-
fibrillation: the HAS-BLED (Hypertension, abnor- tients with non-valvular atrial fibrillation on vita-
mal renal/liver function, stroke, bleeding history or min-K antagonists. Europace 2015;17(5):711-7.
predisposition, labile INR, elderly, drug. J Am Coll
43. Skov J, Bladbjerg E-M, Bor MV, Gram J.
Cardiol 2011;57(2):173-180.
SAMe-TT 2R 2 does not predict time in therapeutic ran-
33. FDA. FDA approves Praxbind, the first reversal ge of the international normalized ratio in patients
agent for the anticoagulant Pradaxa. News Release, . attending a high-quality anticoagulation clinic.
Oct 16, 2015. Silver Spring, MD : FDA; 2015. [upda- Chest 2014;145(1):187-8.
388